WW International (WW) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $192.9 million, down 10.2% year-over-year, with end of period subscribers at 3.7 million, an 8.8% decline from the prior year; clinical subscribers grew 71.5% year-over-year, offsetting declines in Digital and Workshops + Digital segments.

• Interim CEO Tara Comonte emphasized the need to return to sustainable growth amid industry disruption, focusing on leveraging the company’s broad solution portfolio, scientific credibility, and strong brand.

• The company transitioned to a single operating segment structure effective fiscal 2024 and is prioritizing simplification, integration, and revitalization of its brand.

• Recent leadership changes and a renewed focus on core strengths and innovation are expected to drive the next phase of transformation.

• Management remains focused on cost reduction, improved profitability, and unifying solutions to enhance member experience.

Financial highlights

• Subscription revenues were $191.2 million, down 6% year-over-year; Clinical subscription revenues rose 90.7% to $19.1 million.

• Adjusted gross margin reached a record 69.1%, up from 66.2% last year, driven by cost reductions and discontinuation of low-margin products.

• Adjusted operating income was $36 million (18.5% margin), and adjusted EBITDAS was $39.8 million, impacted by $6 million in other expenses.

• Net loss for Q3 2024 was $46.2 million, including $57 million in non-cash franchise rights impairment charges and $13.8–14.8 million in restructuring charges.

• Cash balance at quarter end was $57.2 million, with no outstanding borrowings under the revolving credit facility.

Outlook and guidance

• Full-year 2024 guidance reiterated: at least 3.1 million year-end subscribers, $770 million revenue, $100 million adjusted operating income, and $150 million adjusted EBITDAS.

• Compounded semaglutide launch is not expected to materially impact 2024 results due to its small scale, but clinical subscriber growth continues into Q4.

• Updated full year operating loss guidance to not exceed $240.4 million, reflecting Q3 charges.

• Cost savings of $100 million targeted by end of 2025, with $20 million expected in 2024.

• 2025 revenue will face headwinds from subscriber declines in 2024.